Vivli and RDCA-DAP: Data Platform Partnerships to Promote Rare Disease Data Sharing скачать в хорошем качестве

Vivli and RDCA-DAP: Data Platform Partnerships to Promote Rare Disease Data Sharing

This webinar presentation was held by our collaborator Julie Wood, Chief Operating Officer at Vivli. Julie discussed the activities of Vivli an independent, non-profit organization that has developed a global data-sharing and analytics platform. She also discussed how the Vivli and RDCA-DAP teams are collaborating to promote data sharing in rare diseases. Our panelists from Vivli and C-Path followed the presentation with a broad discussion on how to approach platform to platform collaborations and facilitate data sharing, including a live Q&A. C-Path participants included: Richard Liwski, Alexandre Betourne, and Ramona Walls. SUBSCRIBE to C-Path's YouTube Channel Now ►►    / criticalpathinstitute   FOLLOW C-Path: ►LinkedIn:   / c-path   ►Facebook:   / cpathinstitute   ►Twitter: https://twitter.com/CPathInstitute?re About Critical Path Institute C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org. #CPath #drugdiscovery #researchgrants #globalhealth #drugdevelopment #datasharing #researchfunding #raredisease #academicresearch #regulatoryscience #globalhealth #consortia #collaboration #FDA #EMA #T1D #Parkinsons #Alzheimers #PKD #Duchenne #ALS #biomarkers